https://www.mattheneus.com/editorial/has-rybrevant-early-access-renewal-refusal-final-mariposa2-survival-2026-10-01
#HTA #RegulatoryAffairs
https://www.mattheneus.com/editorial/has-rybrevant-early-access-renewal-refusal-final-mariposa2-survival-2026-10-01
#HTA #RegulatoryAffairs
https://www.mattheneus.com/editorial/has-rybrevant-early-access-renewal-refusal-final-mariposa2-survival-2026-10-01
#HTA #RegulatoryAffairs
https://www.mattheneus.com/editorial/has-rybrevant-early-access-renewal-refusal-final-mariposa2-survival-2026-10-01
#HTA #RegulatoryAffairs
Incorporates findings of #MARIPOSA & #MARIPOSA2: recommends considering Amivantamab in 1° and 2° #EGFR settings with Ex19 or L858R. Both studies improved PFS, OS immature
#medsky #oncsky #lungcancer
ascopubs.org/doi/pdf/10.1...
Incorporates findings of #MARIPOSA & #MARIPOSA2: recommends considering Amivantamab in 1° and 2° #EGFR settings with Ex19 or L858R. Both studies improved PFS, OS immature
#medsky #oncsky #lungcancer
ascopubs.org/doi/pdf/10.1...
In this video, Drs. Desai and Abu Rous discuss trial dates from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
In this video, Drs. Desai and Abu Rous discuss trial dates from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
ADRIATIC
DELPHI-301
LAURA
POLESTAR
MARIPOSA2
PALOMA-3
CROWN
HARMONi
Full session: ow.ly/vpB650UnKyp
#BoOE24 #MedOnc #OncEd
ADRIATIC
DELPHI-301
LAURA
POLESTAR
MARIPOSA2
PALOMA-3
CROWN
HARMONi
Full session: ow.ly/vpB650UnKyp
#BoOE24 #MedOnc #OncEd